Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qiye Shenan Dropping Pill is a Traditional Chinese Medicine (TCM) formulation developed by Xiyuan Hospital of the Chinese Academy of Chinese Medical Sciences, specifically indicated for the treatment of insomnia and related conditions such as anxiety and neurasthenia. The therapeutic effect is derived from the total saponins extracted from the leaves of *Panax notoginseng* (Sanqi), with ginsenoside Rb3 being a major active constituent. These saponins act on the central nervous system to provide sedative and hypnotic benefits, primarily by enhancing the activity of the GABAergic system, which is the brain's principal inhibitory neurotransmitter pathway. The dropping pill dosage form is a modern pharmaceutical technology that allows for rapid disintegration and absorption, offering improved bioavailability and a quicker onset of action compared to traditional herbal tablets or decoctions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on qiye shenan dropping pill.